Last updated: October 2026

Tominersen is an antisense oligonucleotide delivered by spinal injection and being studied to reduce huntingtin production.

Current status

Its development has continued through a revised clinical approach focused on earlier-stage patients. It is not FDA approved, and timing, eligibility, safety, effectiveness, availability, and cost remain uncertain.

For the newest coverage across the HD treatment pipeline, visit What’s Happening in HD Treatment.